OTC TOPICAL ERYTHROMYCIN WOULD LEAD TO INCREASED BACTERIAL RESISTANCE
This article was originally published in The Tan Sheet
Executive Summary
OTC TOPICAL ERYTHROMYCIN WOULD LEAD TO INCREASED BACTERIAL RESISTANCE to the antibiotic, a joint FDA advisory committee unanimously agreed on Nov. 16. Members of FDA's Dermatologic & Ophthalmic Drugs, Anti-Infective Drugs and Nonprescription Drags Advisory Committees voted 15-0 that switching topical erythromycin to over-the-counter status for the treatment of acne would lead to increased bacterial resistance to the drug.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning